Eurofins Scientific SE

WBAG:ESF Stock Report

Market Cap: €8.9b

Eurofins Scientific Valuation

Is ESF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ESF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ESF (€47.07) is trading below our estimate of fair value (€147.67)

Significantly Below Fair Value: ESF is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESF?

Key metric: As ESF is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ESF. This is calculated by dividing ESF's market cap by their current earnings.
What is ESF's PE Ratio?
PE Ratio27.3x
Earnings€325.90m
Market Cap€8.89b

Price to Earnings Ratio vs Peers

How does ESF's PE Ratio compare to its peers?

The above table shows the PE ratio for ESF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average59.5x
QGEN Qiagen
104.6x34.4%US$9.6b
CRL Charles River Laboratories International
24.7x12.4%US$10.1b
TECH Bio-Techne
79.5x21.2%US$11.9b
BRKR Bruker
29x32.3%US$8.7b
ESF Eurofins Scientific
27.3x18.3%€8.9b

Price-To-Earnings vs Peers: ESF is good value based on its Price-To-Earnings Ratio (27.3x) compared to the peer average (59.5x).

Price to Earnings Ratio vs Industry

How does ESF's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ESF 27.3xIndustry Avg. 36.9xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ESF is good value based on its Price-To-Earnings Ratio (27.3x) compared to the European Life Sciences industry average (36.9x).

Price to Earnings Ratio vs Fair Ratio

What is ESF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESF PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ESF's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ESF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€47.07
€59.52
+26.4%
21.0%€89.00€42.00n/a16
Nov ’25€45.82
€59.52
+29.9%
21.0%€89.00€42.00n/a16
Oct ’25€57.56
€60.34
+4.8%
18.8%€90.00€44.00n/a16
Sep ’25€52.08
€59.91
+15.0%
18.6%€90.00€44.00n/a17
Aug ’25€55.30
€60.35
+9.1%
18.1%€90.00€44.00n/a17
Jul ’25€46.85
€59.69
+27.4%
17.1%€83.00€44.00n/a16
Jun ’25€55.34
€60.88
+10.0%
15.0%€83.00€48.00n/a16
May ’25€58.32
€60.88
+4.4%
15.0%€83.00€48.00n/a16
Apr ’25€57.02
€59.03
+3.5%
15.7%€84.00€48.00n/a16
Mar ’25€55.88
€58.66
+5.0%
14.5%€80.00€48.00n/a17
Feb ’25€55.50
€57.42
+3.5%
16.4%€80.00€45.00n/a17
Jan ’25€59.24
€57.65
-2.7%
16.4%€80.00€45.00n/a17
Dec ’24€53.20
€57.92
+8.9%
17.7%€81.00€45.00n/a17
Nov ’24€47.73
€61.98
+29.8%
24.6%€105.00€45.00€45.8217
Oct ’24€53.84
€65.79
+22.2%
20.2%€105.00€48.00€57.5617
Sep ’24€56.40
€66.88
+18.6%
21.5%€105.00€48.00€52.0815
Aug ’24€62.48
€66.61
+6.6%
20.8%€105.00€48.00€55.3015
Jul ’24€56.58
€66.80
+18.1%
19.6%€105.00€50.00€46.8516
Jun ’24€61.14
€65.98
+7.9%
20.1%€105.00€50.00€55.3417
May ’24€60.56
€67.22
+11.0%
21.5%€105.00€50.00€58.3217
Apr ’24n/a
€68.92
0%
20.9%€105.00€50.00€57.0215
Mar ’24n/a
€73.85
0%
19.5%€105.00€51.92€55.8814
Feb ’24€66.04
€78.53
+18.9%
23.4%€125.00€51.92€55.5015
Jan ’24€68.62
€81.85
+19.3%
21.3%€125.00€51.92€59.2414
Dec ’23€68.20
€82.07
+20.3%
21.3%€125.00€51.92€53.2014
Nov ’23€64.20
€84.62
+31.8%
21.1%€125.00€51.92€47.7316

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$15.60

7D

-4.3%

1Y

72.6%

Bayer

€19.0b

Operates as a life science company worldwide.

BAYN

€19.37

7D

-0.9%

1Y

-38.3%

Merck KGaA

€61.3b

Operates as a science and technology company in Germany.

MRCK

€140.95

7D

1.9%

1Y

-11.7%